|
|
|
|
| LEADER |
01726nam a2200337 u 4500 |
| 001 |
EB001897166 |
| 003 |
EBX01000000000000001060171 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200523 r ||| eng |
| 100 |
1 |
|
|a Williams, D.
|
| 245 |
0 |
0 |
|a Glatiramer acetate and interferon beta 1a and 1b for clinically isolated syndrome
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|c authors, Dinsie Williams, Robyn Butcher
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c September 18, 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (32 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Interferon beta-1b / therapeutic use
|
| 653 |
|
|
|a Glatiramer Acetate / therapeutic use
|
| 653 |
|
|
|a Interferon beta-1a / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Practice Guidelines as Topic
|
| 653 |
|
|
|a Demyelinating Diseases / drug therapy
|
| 700 |
1 |
|
|a Butcher, Robyn
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK549582
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This review aims to summarize and evaluate evidence regarding the clinical effectiveness and safety of glatiramer acetate, IFN beta-1a, and IFN beta-1b, in treating patients with clinically isolated syndrome (CIS). The review also aims to summarize and assess relevant evidence-based guidelines
|